{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:47Z","timestamp":1787019647070,"version":"build-2736575974"},"reference-count":28,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2021,9,26]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>A decreasing trend in exacerbation rates has been observed in COPD. Because mortality is linked to exacerbations, it is of interest to investigate whether a similar time trend is also present in mortality rates.<\/jats:p>\n                  <jats:p>We performed a systematic review of placebo groups in published randomised controlled trials. Mortality rate was modelled based on a Poisson distribution for the event counts. Adding information on mortality as well as on newly published studies on a previous database, we performed a meta-regression.<\/jats:p>\n                  <jats:p>Among the 56 included studies representing 14\u200a166 patients, an annual decrease in mortality rates of 6.1% (\u22120.6%, 12.6%) (p=0.073) was observed. Consistent results were obtained in subgroups as well as when adjusting for potential confounders. The correlation between exacerbation rate and mortality rate was positive but weak as well as insignificant.<\/jats:p>\n                  <jats:p>In summary, analysis of randomised controlled trials in COPD patients showed a decrease in mortality in the placebo arms over the last two decades. This effect is comparable to the previously observed decrease in annual exacerbation rate. Albeit insignificant, our results suggest that care is needed in the design of new trials or when comparing results from trials published many years apart.<\/jats:p>","DOI":"10.1183\/23120541.00261-2021","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T10:01:49Z","timestamp":1633687309000},"page":"00261-2021","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["COPD mortality and exacerbations in the placebo group of clinical trials over two decades: a systematic review and meta-regression"],"prefix":"10.1183","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-6909","authenticated-orcid":false,"given":"Stefan","family":"Andreas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-698X","authenticated-orcid":false,"given":"Christian","family":"R\u00f6ver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Heinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Taube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5347-7441","authenticated-orcid":false,"given":"Tim","family":"Friede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"2024101711225185000_8.1.00261-2021.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1900500"},{"key":"2024101711225185000_8.1.00261-2021.2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30105-3","article-title":"Prevalence and attributable health burden of chronic respiratory diseases, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"8","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2024101711225185000_8.1.00261-2021.3","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-201518"},{"key":"2024101711225185000_8.1.00261-2021.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01391-2014"},{"key":"2024101711225185000_8.1.00261-2021.5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12931-019-1163-2","article-title":"Decline of COPD exacerbations in clinical trials over two decades \u2013 a systematic review and meta-regression","volume":"20","author":"Andreas","year":"2019","journal-title":"Respir Res"},{"key":"2024101711225185000_8.1.00261-2021.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713901"},{"key":"2024101711225185000_8.1.00261-2021.7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"key":"2024101711225185000_8.1.00261-2021.8","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00634-2020"},{"key":"2024101711225185000_8.1.00261-2021.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"2024101711225185000_8.1.00261-2021.10","unstructured":"European Medicines Agency. Guideline on clinical investigations of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD). 2012. www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-chronic-obstructive-pulmonary-disease_en.pdf"},{"key":"2024101711225185000_8.1.00261-2021.11","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2007.082636"},{"key":"2024101711225185000_8.1.00261-2021.12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/bimj.201300288","article-title":"Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data","volume":"58","author":"Rover","year":"2016","journal-title":"Biom J"},{"key":"2024101711225185000_8.1.00261-2021.13","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"2024101711225185000_8.1.00261-2021.14","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2147\/COPD.S215011","article-title":"Efficacy and safety of once-daily inhaled umeclidinium in Asian patients with COPD: results from a randomized, placebo-controlled study","volume":"15","author":"Zhong","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2024101711225185000_8.1.00261-2021.15","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1177\/1352458518794063","article-title":"Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: a systematic review and meta-analysis of 43 randomised placebo-controlled trials","volume":"25","author":"Nicholas","year":"2019","journal-title":"Mult Scler"},{"key":"2024101711225185000_8.1.00261-2021.16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137052"},{"key":"2024101711225185000_8.1.00261-2021.17","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513481009"},{"key":"2024101711225185000_8.1.00261-2021.18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ejhf.2103","article-title":"Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta-regression in the past four decades","volume":"23","author":"Kimmoun","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2024101711225185000_8.1.00261-2021.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006720"},{"key":"2024101711225185000_8.1.00261-2021.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02470-2016"},{"key":"2024101711225185000_8.1.00261-2021.21","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"key":"2024101711225185000_8.1.00261-2021.22","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00055-2016"},{"key":"2024101711225185000_8.1.00261-2021.23","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/eurheartj\/ehy451","article-title":"Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial","volume":"39","author":"Byrd","year":"2018","journal-title":"Eur Heart J"},{"key":"2024101711225185000_8.1.00261-2021.24","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2021 Report. 2020. https:\/\/goldcopd.org\/wp-content\/uploads\/2020\/11\/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf"},{"key":"2024101711225185000_8.1.00261-2021.25","doi-asserted-by":"crossref","first-page":"e1002958","DOI":"10.1371\/journal.pmed.1002958","article-title":"Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis","volume":"16","author":"Lee","year":"2019","journal-title":"PLoS Med"},{"key":"2024101711225185000_8.1.00261-2021.26","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00128806"},{"key":"2024101711225185000_8.1.00261-2021.27","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1680"},{"key":"2024101711225185000_8.1.00261-2021.28","doi-asserted-by":"publisher","DOI":"10.3414\/ME09-02-0060"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00261-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:12:34Z","timestamp":1740355954000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00261-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3,7]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1183\/23120541.00261-2021"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00261-2021","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]}}}